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Abstract
Background: Although the association between H. pylori and gastric cancer has been well described, the alterations
studies are scarce in the humoral immune response in specific anatomical areas of stomach and during the stages of
gastric cancer. The aim in this study was to determine the influence of humoral immune responses against H. pylori
infection on gastric carcinoma.
Methods: We selected 16 gastric cancer cases and approximately one matched control per case at the National
Institute of Medical Sciences and Nutrition Salvador Zubirán (INCMNSZ); all the cases met the inclusion criteria for
the study. We obtained three biopsies from each patient and from each of the predetermined regions of the stomach:
antrum, angular portion, corpus, and fundus. From the patients with gastric cancer, additional biopsy specimens were
obtained from tumor mid-lesion and tumor margin, and additional specimens were collected at least 2 and 5 cm from
the tumor margin. We compared IgA levels against H. pylori in each area of stomach between cases and controls as
well as between early and advanced stages of gastric cancer.
Results: IgA values were strikingly elevated in cancer cases compared with control subjects; a value that was even higher
in the distant periphery of tumor but was remarkably decreased toward the carcinoma lesion. The advanced stages of
gastric cancer demonstrated the relapse of the humoral immune response in the mid-lesion region of the tumor
compared with the tumor margins and adjacent non-tumor tissue.
Conclusions: Gastric cancer is characterized by progressive accumulation of a concentrated, specific IgA response
against H. pylori, beginning with an abnormal increase in the entire stomach but particularly in the adjacent non-tumor
tissue. Thus, it is possible that this strong immune response also participates in some degree in the damage and in the
development of gastric cancer to some extent.
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Background
Helicobacter pylori is a human pathogen that colonizes
gastric mucosa and afflicts approximately half of the
world’s population [1]. H. pylori infection is acquired
mainly in the first years of life and persists for decades,
causing chronic gastritis, duodenal ulcers, and gastric
ulcers, and is a significant risk factor for the development
of gastric adenocarcinoma [2]. The nature of gastroduode-
nal pathologies depends on the anatomical site of H. pylori
infection in the stomach. We previously showed that the
antrum and the corpus are the major anatomic sites
colonized by H. pylori in patients with gastric cancer
[3]. However, only a third of the gastric biopsies were
positive for H. pylori, and its colonization was higher
inside the tumor lesion compared with the surround-
ing non-tumor tissue. Therefore, it is tempting to
speculate that vigorous abnormal immune responses
at the local level are associated with the clearance of
H. pylori infection and with gross pathology. Gastric
adenocarcinoma develops as a consequence of chronic
inflammation of the stomach lining caused by persist-
ent infection with H. pylori [4]. Gastric carcinogenesis
progresses through a sequence of preneoplastic
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lesions that manifest histologically as atrophic gastri-
tis, intestinal metaplasia, and dysplasia [5]. Although
a minority of infected people develops gastric cancer,
this disease is the second leading cause of cancer
death worldwide, partly because patients are not diag-
nosed until late-stage cancer is present and a poor
prognosis [2].
H. pylori bacteria persist in spite of activation of the
host’s innate and adaptive immune response [6]. Anti-
body production and cellular immune responses are not
concordant with immunological memory against H. pylori
infection [7]. Moreover, the bacteria seem to actively
dampen the T-helper 1 (Th1) response, which is charac-
terized by T cell activation (CD8 and CD4 positive T cells)
and IFN-γ production, leading to considerable tissue dam-
age [8, 9]. Factors other than H. pylori infection, which
can predispose an individual to gastric cancer have been
identified, among them are achlorhydria and oxyntic atro-
phy [10]. However, the relationship between gastric cancer
development and the strength of local humoral immune
responses against H. pylori is poorly understood.
IgA and IgG are the main effectors of the humoral im-
mune responses against H. pylori infection in the gastric
mucosa [4, 11, 12]. Unlike IgA, IgG is not actively secreted
through the gastric mucosa; thus its protective function in
the gastric lumen is limited [13]. Although IgA is actively
secreted to the gastric lumen, where its effectors function
is achieved, it is also present in the systemic circulation
[14, 15]. Previous studies have shown that elevated serum
levels of anti-H. pylori IgA is a sensitive indicator of
gastric cancer risk [16, 17].
To determine the influence of humoral immune re-
sponses against H. pylori infection on gastric carcinoma,
we assessed the presence of anti-H. pylori IgG and IgA
levels in gastric adenocarcinoma patients and non-cancer
patients by ELISA. We used tissue homogenates of dif-
ferent anatomical areas of the stomach and at the mid-
lesion and marginal areas of the carcinoma lesion as
well as nearby tumor-free tissue.
Methods
Patients and sampling
We used gastric samples from a previous study [3], in
which patients underwent gastrointestinal endoscopy to
rule out cancer and dyspeptic symptoms. Conducted
between November 2006 and November 2007, the study
included thirty-two patients recruited at the Endoscopic
Service at the National Institute of Medical Sciences and
Nutrition “Salvador Zubirán” (INCMNSZ). All samples
were obtained with the written informed consent of the
patients, given prior to their inclusion in the study and
were in accordance with the Helsinki Declaration. This
study was approved by the Ethics and Investigation
Committee of National Institute of Medical Sciences and
Nutrition “Salvador Zubirán”, registry number CIBH-
1081. The subjects recruited were included in gastric can-
cer or control (non-cancer) groups; endoscopic diagnosis
was confirmed by histological examination. A systematic
biopsy-sampling scheme was used in order to obtained a
maximum of three biopsies per patient from each predeter-
mined regions of stomach: the antrum, angular portion,
corpus and fundus. From the patients with possible gastric
cancer, additional biopsy specimens were obtained from
the mid-lesion of the tumor, the tumor margin, and at least
2 and 5 cm from the tumor margin. One part of each sam-
ple was snap-frozen and then stored at −70 °C until use.
The other part was fixed in 10 % formalin and embedded
in paraffin for histopathological examination. After diagno-
ses were confirmed, two patients in the cancer group were
excluded from the study since they had MALT lymphoma.
All patients with non-ulcer dyspepsia and/or gastro-
esophageal reflux were considered the control group
(non-cancer group). The groups were constituted as
shown in Table 1.
Preparation of the strains to coated the ELISA plates
The H. pylori strains 26695 and J99 (ATCC 700392 and
700824, respectively) were growth on Casman agar
(DIFCO) supplemented with 10 % defibrinated horse
serum (Horse serum ATCC; Manassas, Va) and incu-
bated at 36 ± 1 °C during 72 h in microaerophilic condi-
tions. A Gram strain was performed to make sure that
more than 90 % of the bacteria were bacilli. The strains





Mean age, yr (± SD) 57.6 ± 16.7 47.2 ± 13.3
Gender (Male/Female) 9/7 2/12
H. pylori colonizationb 93.8 %* 64.3 %
Early stage of cancer (I and II) 5 -
Advanced stage of cancer (III and IV) 11 -
Positivity to H. pylori of each anatomic site
Fundus 50 35.7
Corpus 56.2 50




Tumor margin 68.8 -
At least 2 cm** 62.5 -
At least 5 cm** 56.3 -
aFrom our previous report [3]
bH. pylori was identified either by culture or PCR
cH. pylori-colonization in the tumor sites was 81.3 %
*p < 0.05
**At least 2 and 5 cm away from tumor margin
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were harvested in sterile isotonic saline solution (SISS),
adjusted to 0.5 McFarland tube (1.5 × 108 CFU/mL), and
mixed 1:1 (v/v). The bacterial suspension was formalin
treated with a 0.6 % formaldehyde solution v/v during
48 h at room temperature. Then, the bacterial suspen-
sion was centrifuged at 2,500 rpm and washed with SISS.
This procedure was repeated once more; the bottom was
re-suspended in SISS. The bacterial suspension was
quantified by the Bradford method in order to know the
concentration of the surface proteins.
Measurement of in situ levels of IgG and IgA against H. pylori
We compared anti-H. pylori IgG and IgA levels, as mea-
sured by ELISA, in each region between cases and controls
and in early (I and II) and advanced (III and IV) stages of
gastric cancer. Each biopsy sample was homogenized indi-
vidually in 50 μL of cold PBS (pH 7.4) using a glass tissue
grinder on ice; the sample was subsequently adjusted to
500 μL. We took 100 μL of the sample and added 20 μL of
a protease inhibitor cocktail (Complete, Roche Diagnostic
GmbH, Mannheim, Germany) and 380 μL of 2 % saponin
in PBS (JT Baker; Phillipsburg, NJ, USA). After overnight
maceration at 4 °C, samples were centrifuged at 13,000 × g
for 10 min. The protein concentration was determined and
adjusted in all samples. One hundred μL of the superna-
tants were collected and individually tested for IgG and
IgA levels by an indirect ELISA. Duplicate assay were per-
formed for each immunoglobulin tested. The plates
(NUNC MaxiSorp; Rochester, NY, USA) were coated with
100 μL of 10 μg/ml bacterial suspension in carbonate buf-
fer pH 9.4 and incubated at 4 °C overnight. They washed
three times with 0.5 % Tween 20 in phosphate buffered sa-
line (PBS, pH 7.4). One hundred μL of each sample were
inoculated in the ELISA plate and incubated for 1.5 h at
room temperature. Antibodies (anti-human IgG and IgA,
HRP-conjugated) were purchased from ZYMED Labora-
tories (Invitrogen; Carlsbad, CA, USA) and used at 1:5,000
for 1 h at 37 °C. After washing, substrate solution was
added and the colorimetric reaction was stopped at 15
min. The ELISA plates were then read using a microplate
reader (GENios Plus, Tecan Austria GmbH, Grödig,
Austria). The results are given as the median ± interquar-
tile range of the optical density values (450 nm) of each
group. Positive and negative controls were serum ob-
tained from patients of previous study [18].
Determination of IgG1 and IgG2 antibody titer
96-well white polystyrene assay plates (Costar, Corning
Inc., Lowell, MA, USA) were coated with 100 μL of 10
μg/ml bacterial suspension in carbonate buffer pH 9.4
and incubated at 4 °C overnight. The wells were then
blocked with 5 % skim milk in PBS for 1 h, and then
washed with 0.5 % Tween 20 in PBS. The patients’ sera
were serially diluted in the wells and incubated for 1 h
at 37 °C. After washing away the primary antibody, a mix-
ture of secondary antibodies was added at final concentra-
tions of 1:1,000 (α-IgG1) and 1:500 (α-IgG2). These
secondary antibodies (α-IgG1, HRPO conjugated) were
purchased from CALTAG Laboratories (Burlingame, CA,
USA) and ZYMED (α-IgG2 AP conjugate, San Francisco,
CA, USA). After 1 h of incubation, the plates were washed
and Luminata Crescendo ELISA HPR substrates (Millipore
Corporation, USA) were added sequentially to detect the
IgG1 and IgG2 antibodies. The plates were then read using
a microplate reader (GENios Plus, Tecan Austria GmbH,
Grödig, Austria). The antibody titer was calculated by plot-
ting luminescence versus serum dilution; the luminescence
value was 1 above the background while the data were
analysed by calculating the log10 of the titre dilution as
described by Martinez-Becerra et al., [19].
Detection of H. pylori colonization
We have previously reported the H. pylori colonization
status of the patients in this study [3]. We smeared an
aliquot of the biopsy-homogenates previously described
onto Casman agar plates (BBL Microbiology Systems,
Cockeysville, MD, USA) for culture of H. pylori. Biopsies
with negative culture were also tested by 16S rRNA PCR
according to Castillo-Rojas et al. [18]. Biopsies that were
positive by culture or PCR were considered positive for
H. pylori colonization. Biopsies were defined as H. pyl-
ori-negative if both results were negative.
Statistical analysis
We had a maximum of three biopsy samples for each ana-
tomical location. We obtained a single estimation for each
biopsy location by calculating their arithmetic mean.
Given that the tissue levels of immunoglobulin calculated
in this way showed a right-skewed distribution, we used
the median value as an index of central tendency and the
interquartile range (IQR) to summarize the distribution.
Patients with gastric cancer were divided into two sub-
groups according to their TNM stage: early gastric cancer
subgroup for those in stage 0, I or II, and advanced gastric
cancer subgroup for those in stage III or IV. Statistical
comparisons of IgG and IgA levels were performed by the
presence or absence of gastric cancer in the studied pa-
tients for each location as well as early and late stages of
cancer in cancer patients through the rank sum test. We
also tested the significance of differences between the pre-
determined locations, both in cancer and non-cancer pa-
tients, as well as between the tumor sampled sites in the
cancer patients with the Friedman test (non-parametric
procedure for a repeated measurements design with more
than two repetitions per subject) [20]. The correlation of
serum IgG with tissue IgG was measured with the Spear-
man’s rho coefficient. Given that, for each immunoglobu-
lin, five different comparisons were performed, according
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to Bonferroni’s procedure, alpha value was adjusted to de
0.01 (two tailed) level. Calculations were performed with
the Stata software (StataCorp. 2005. Stata Statistical Soft-
ware: Release 9. College Station, TX: StataCorp LP).
Results
Of the 30 patients that were recruited for the study, 16
were diagnosed with gastric cancer after endoscopic and
histological examination, and the remaining 14 were posi-
tive for dyspepsia. A maximum of three biopsies of spe-
cific gastric anatomical sites were obtained per patient. As
previously reported, sampled of gastric cancer patients
were obtained from the tumor site, the tumor margin, and
at least two and five centimeters beyond the margin [3].
We found that 64.3 % of the patients of the normal ana-
tomical and 93.8 % of the gastric cancer patient areas were
colonized by H. pylori. For their part, biopsies from the
middle lesion, the margin, at least 2 and plus 5 cm, were
colonized in 68.8, 68.8, 62.5 and 56.3 %, respectively. We
found a discrete, but consistent relationship between the
tissue dysplasia and the grade of colonization by H. pylori
(Table 1). On the other hand, the rest of patients were
negative for both the culture and PCR.
The results of tissue immunoglobulin assays in patients
with and without gastric cancer are shown in Table 2. The
more striking differences are evident in the significant IgA
increase in the predetermined sites of stomach in the pa-
tients with gastric cancer compared with tumor-free pa-
tients (Optical Density median, IQR: antrum 0.868,
0.578–0.945 vs. 0.176, 0.129–0.867; p =NS; angular por-
tion 0.802, 0.637–1.051 vs. 0.275, 0.135–0.945, p =NS; cor-
pus 0.836, 0.688–1.039 vs. 0.413, 0.134–0.737, p = 0.006;
Table 2 Determination of IgA and IgG antibodies against H. pylori in gastric tissue by sampling site and presence of gastric cancer
Immunoglobulin A
Non-cancer n (14) Gastric cancer n (16)
Sampling site OD Median (IQR) OD Median (IQR) p value*
Antrum 0.176 (0.129–0.867) 0.868 (0.578–0.945) NS
Corpus 0.413 (0.134–0.737) 0.836 (0.688–1.039) 0.0068
Fundus 0.267 (0.160–0.675) 0.772 (0.668–1.115) NS
Angular portion 0.275 (0.135–0.945) 0.802 (0.637–1.051) NS
p value (predetermined sites) NS NS
Mid-lesion . 0.419 (0.152–0.736)
Tumor margin . 0.902 (0.536–0.975)
At least 2 cm . 0.976 (0.606–1.220)
At least 5 cm . 0.919 (0.753–1.293)
p value (tumor sites) 0.001
p value (predetermined sites + tumor sites) 0.0048
Immunoglobulin G
Non-cancer n (14) Gastric cancer n (16)
Sampling site OD Median (IQR) OD Median (IQR) p value*
Antrum 0.125 (0.107–0.615) 0.200 (0.160–0.375) NS
Corpus 0.199 (0.115–0.326) 0.335 (0.226–0.627) NS
Fundus 0.135 (0.116–0.462) 0.342 (0.161–0.527) NS
Angular portion 0.151 (0.103–0.608) 0.247 (0.157–0.349) NS
p value (predetermined sites) NS NS
Mid-lesion . 0.193 (0.119–0.311)
Tumor margin . 0.300 (0.138–0.463)
At least 2 cm . 0.276 (0.165–0.631)
At least 5 cm . 0.215 (0.164–0.445)
p value (tumor sites) 0.005
p value (predetermined sites + tumor sites) NS
OD Optical Density, IQR interquartile range
*Non-cancer vs Gastric cancer
NS not significant
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fundus 0.772, 0.668–1.115 vs. 0.267, 0.160–0.675, p =NS).
Additionally, it is clear that a differential distribution
within tumor sites was observed in the patients with gas-
tric cancer; the center samples showed the lowest values
(Optical Density median, IQR: 0.419, 0.152–0.736) com-
pared with the rest of the stomach (Optical Density me-
dian, IQR: tumor margin 0.902, 0.536–0.975; at least 2 cm
0.976, 0.606–1.220; at least 5 cm 0.919, 0.753–1.293), hav-
ing significant differences (p = 0.001) even with the prede-
termined normal anatomical sites (p = 0.004). Although
IgG levels were also higher in the anatomical sites of the
stomach in patients with gastric cancer compared with
controls, the differences were not statistically significant.
However, the center of the tumor had the lowest IgG
values (Optical Density median, IQR 0.193, 0.119–0.311)
while higher levels were found farther away from the cen-
ter of the tumor (Optical Density median, IQR: tumor
margin 0.300, 0.138–0.463; at least 2 cm 0.276, 0.165–
0.631; at least 5 cm 0.215, 0.164–0.445), a difference that
was statistically significant (p = 0.005).
When cancer patients were further divided into early
(I and II) or advanced (III and IV) stages, differences
were also found in immunoglobulin distribution across
the tumor sites in the “advanced” gastric cancer patients
(Table 3). The tumor center remained the site with the
lowest values, both for IgG (Optical Density median, IQR
0.151, 0.103–0.233) and IgA (Optical Density median,
IQR 0.273, 0.150–0.632). The comparison of patients in
the early stage of gastric cancer with those without cancer
Table 3 Determination of IgA and AgG antibodies against H. pylori in gastric tissue from gastric cancer group by sampling site and
cancer stage
Immunoglobulin A
Early gastric cancer n (5) Advanced gastric cancer n (12)
Sampling site OD Median (IQR) OD Median (IQR) p value*
Antrum 0.913 (0.578–0.937) 0.825 (0.689–0.945) NS
Corpus 0.870 (0.688–0.957) 0.823 (0.735–1.039) NS
Fundus 0.668 (0.668–0.772) 0.851 (0.717–1.115) NS
Angular portion 0.637 (0.637–0.833) 0.881 (0.744–1.075) NS
p value (predetermined sites) NS NS
Mid-lesion 0.811 (0.474–0.827) 0.273 (0.150–0.632) NS
Tumor margin 0.941 (0.762–1.147) 0.889 (0.484–0.965) NS
At least 2 cm 1.175 (0.606–1.220) 0.869 (0.628–1.225) NS
At least 5 cm 0.919 (0.753–0.928) 0.915 (0.642–1.308) NS
p value (tumor sites) NS 0.0023
p value (predetermined sites + tumor sites) NS 0.0083
Immunoglobulin G
Early gastric cancer n (5) Advanced gastric cancer n (12)
Sampling site OD Median (IQR) OD Median (IQR) p value*
Antrum 0.375 (0.192–0.563) 0.182 (0.156–0.289) NS
Corpus 0.473 (0.273–0.513) 0.285 (0.175–0.627) NS
Fundus 0.516 (0.340–0.527) 0.299 (0.159–0.441) NS
Angular portion 0.258 (0.236–0.550) 0.222 (0.142–0.348) NS
p value (predetermined sites) NS NS
Mid-lesion 0.285 (0.281–0.534) 0.151 (0.103–0.233) NS
Tumor margin 0.508 (0.463–0.565) 0.221 (0.119–0.348) NS
At least 2 cm 0.631 (0.296–0.926) 0.212 (0.133–0.501) NS
At least 5 cm 0.439 (0.215–0.558) 0.188 (0.161–0.372) NS
p value (tumor sites) NS 0.0097
p value (predetermined sites + tumor sites) NS NS
OD Optical Density, IQR interquartile range
*Early gastric cancer vs Advanced gastric cancer
NS not significant
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was not statistically significant (p = 0.08 and p = 0.06 for
IgA in the antrum and corpus, respectively), although the
early gastric cancer was small (n = 5).
Serum determinations of IgG1 and IgG2 showed no
difference in medians in both groups studied (data not
shown). Correlation of serum and tissue immunoglobu-
lins did not show a significant trend in either for the
whole group or for the subgroups of presence of gastric
cancer or of H. pylori (Table 4).
Discussion
The systematic analysis of IgA and IgG levels across dif-
ferent normal regions of the stomach (antrum, angular
portion, corpus, and fundus), and the primary tumor and
its surrounding tissue, allow us to define the dynamics
of the humoral immune response against H. pylori and
its association with the tissue pathology.
Topographic analysis showed that IgA levels were
higher than IgG levels, except in the region of corpus
where, coincidently, H. pylori colonized in higher fre-
quency [3, 18]. Patients with gastric cancer had twice as
much anti-H. pylori IgA than control patients, although
IgG levels were similar in all patients. It is clear that the
primary tumor expressed less IgA and IgG than the rest of
the tissue, which had an abnormal higher production of
IgA compared with controls. This increase in IgA secre-
tion in the infected tissue correlates with previous studies
that demonstrated serum IgA values might indicate gastric
cancer risk development.
On the contrary, reduced levels in the center of the
tumor led us to speculate that the damage to the tissue
induced by chronic infection with H. pylori affects the
production of immunoglobulin. Quiding-Järbrink et al.,
[21] shown a decrease in IgA production in the stomach
of patients with gastric cancer, suggesting that low levels
of antibody production could be an indicative of risk for
gastric cancer development in the case of precancerous
atrophic gastritis caused by H. pylori. On the other hand,
Adamsson et al., [22] found reduced IgA levels in the
non-tumor tissue from gastric cancer patients, suggested
that this must be used as a marker for the detection of
risk cancer group and early stage of gastric cancer. This
study confirmed de early study of Quiding-Järbrink et al.
Furthermore; we found similar results in the IgA antibody
levels in the patients with GC as in the control group H.
pylori positive (data not shown), as in Adamsson et al.,
study [22].
Contrary our findings disagree with this previous re-
ports in which cancer patients in various stages of gastric
cancer progression were examined; in as much as more
advanced cancers were associated with decreased antibody
production. Conversely, we found an increase of IgA in
the tissue of patients with gastric cancer, probably this is
due by the changes in the H. pylori phenotypes during the
development of gastric cancer, as we previous report [3],
we found high genotypic diversity in the gastric cancer
group. Quiding-Järbrink et al., [21] suggested that a shift
in antigens expression would probably lead to production
of antibodies to the newly expressed antigens.
Previous studies have shown that IgA antibodies against
H. pylori are detected in gastric tissue and saliva [23, 24].
Together with this data, we found a higher production of
IgA in the tissue of patients with early and advanced gas-
tric cancer stages compared with those patients without
cancer. Then, detection of IgA antibodies against H. pylori
in saliva should be increased at least two-fold. This will be
a useful method to detected patients in early stages with
increased risk of gastric cancer. This must be corroborat-
ing with a conducted study in future.
Conclusions
In conclusion, gastric cancer is characterized by progres-
sive accumulation of a concentrated, specific IgA response
against H. pylori, beginning with an abnormal increase in
the entire stomach but particularly in the adjacent non-
tumor tissue. Thus, this strong immune response may also
take part in the damage to some degree as suggested by
the higher levels of humoral immune responses nearest to
the tumor as compared to the adjacent normal tissue.
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